These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15904772)

  • 1. [Osteogenesis imperfecta and bisphosphonates].
    Forin V
    Arch Pediatr; 2005 Jun; 12(6):688-90. PubMed ID: 15904772
    [No Abstract]   [Full Text] [Related]  

  • 2. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: a case series.
    Schwartz S; Joseph C; Iera D; Vu DD
    J Can Dent Assoc; 2008; 74(6):537-42. PubMed ID: 18644240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates in children with bone diseases.
    Plotkin H
    N Engl J Med; 2003 Nov; 349(21):2068-71; author reply 2068-71. PubMed ID: 14627793
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravenous pamidronate treatment in osteogenesis imperfecta.
    Fujiwara I; Ogawa E; Igarashi Y; Ohba M; Asanuma A
    Eur J Pediatr; 1998 Mar; 157(3):261-2. PubMed ID: 9537501
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of osteogenesis imperfecta with bisphosphonates].
    Tau C
    Medicina (B Aires); 2007; 67(4):389-95. PubMed ID: 17891938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrease of serum alkaline phosphatase after three cycles of pamidronate disodium in children with severe osteogenesis imperfecta.
    Cabral de Menezes Filho H; Rodrigues JM; Radonsky V; Della Manna T; Kuperman H; Steinmetz L; Dichtchekenian V; Damiani D; Setian N
    Horm Res; 2007; 68 Suppl 5():207-8. PubMed ID: 18174750
    [No Abstract]   [Full Text] [Related]  

  • 7. High levels of serum prostaglandin E2 in children with osteogenesis imperfecta are reduced by neridronate treatment.
    D'Eufemia P; Finocchiaro R; Celli M; Zambrano A; Tetti M; Villani C; Persiani P; Mari E; Zicari A
    Pediatr Res; 2008 Feb; 63(2):203-6. PubMed ID: 18091347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate treatment of bone disease.
    Shaw NJ; Bishop NJ
    Arch Dis Child; 2005 May; 90(5):494-9. PubMed ID: 15851432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates.
    Malmgren B; Aström E; Söderhäll S
    J Oral Pathol Med; 2008 Apr; 37(4):196-200. PubMed ID: 18321345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta.
    Kamoun-Goldrat A; Ginisty D; Le Merrer M
    Eur J Oral Sci; 2008 Jun; 116(3):195-8. PubMed ID: 18471236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with bisphosphonates in osteogenesis imperfecta.
    Glorieux FH
    Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alendronate treatment in children with osteogenesis imperfecta.
    Akcay T; Turan S; Guran T; Bereket A
    Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
    Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
    Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
    D'Eufemia P; Finocchiaro R; Zambrano A; Tetti M; Ferrucci V; Celli M
    Biomed Pharmacother; 2007 May; 61(4):235-40. PubMed ID: 17275249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary function tests in an infant with osteogenesis imperfecta and early biphosphonate treatment.
    Rugolotto S; Monti E; Carli M; Pietrobelli A; Antoniazzi F; Tato L
    Acta Paediatr; 2007 Dec; 96(12):1856-7. PubMed ID: 18001342
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta.
    Land C; Rauch F; Montpetit K; Ruck-Gibis J; Glorieux FH
    J Pediatr; 2006 Apr; 148(4):456-60. PubMed ID: 16647404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteogenesis imperfecta.
    Huber MA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103(3):314-20. PubMed ID: 17223585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonate treatment in osteogenesis imperfecta: which drug, for whom, for how long?
    Rauch F; Glorieux FH
    Ann Med; 2005; 37(4):295-302. PubMed ID: 16019729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates in osteogenesis imperfecta.
    Shaw NJ
    Arch Dis Child; 1997 Jul; 77(1):92-3. PubMed ID: 9279168
    [No Abstract]   [Full Text] [Related]  

  • 20. [Bisphosphonate treatment of children and adolescents].
    Illum NO
    Ugeskr Laeger; 2003 Jan; 165(5):454-6. PubMed ID: 12599842
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.